Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-22-073980
Date:2022-06-21
Issuer: CULLINAN ONCOLOGY, INC. (CGEM)
Original Submission Date:

Reporting Person:

F2 BIOSCIENCE I 2017 LTD
C/O LJ MANAGEMENT (SUISSE) SA
8, RUE SAINT-LEGER GENEVA, V8 CH-1205

Reporting Person:

JOVAN-EMBIRICOS MORANA
C/O LJ MANAGEMENT (SUISSE) SA
8, RUE SAINT-LEGER GENEVA, V8 CH-1205

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2022-06-21 S 22,319 d $12.77 616,976 f2 direct
COMMON STOCK 2022-06-22 S 49,953 d $12.70 567,023 f2 direct
COMMON STOCK 2022-06-23 S 29,631 d $13.00 537,392 f2 direct
COMMON STOCK 2022-06-21 0 $0.00 1,136,525 indirect f5
COMMON STOCK 2022-06-21 0 $0.00 1,305,873 indirect f6
COMMON STOCK 2022-06-21 0 $0.00 325,333 indirect f7
COMMON STOCK 2022-06-21 0 $0.00 622,175 indirect f8
COMMON STOCK 2022-06-21 0 $0.00 71,599 indirect f9
COMMON STOCK 2022-06-21 0 $0.00 214,798 indirect f10
COMMON STOCK 2022-06-21 0 $0.00 104,762 indirect f11
COMMON STOCK 2022-06-21 0 $0.00 112,507 indirect f12
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission ("sec"), upon request, full information regarding the number of shares sold at each separate price within the range.
f2 these securities are owned directly by f2 bioscience i 2017 limited ("f2 bioscience 2017"). globeways holdings limited ("globeways") is the appointed manager of f2 bioscience 2017. dr. morana jovan-embiricos is the founding director of globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2 bioscience 2017. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the sec, upon request, full information regarding the number of shares sold at each separate price within the range.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the sec, upon request, full information regarding the number of shares sold at each separate price within the range.
f5 these securities are owned directly by globeways. dr. jovan-embiricos is the founding director of globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by globeways. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f6 these securities are owned directly by f2 vision scs ("f2 vision"). f2 vision management sarl ("f2 vision management") is the appointed manager of f2 vision. dr. jovan-embiricos is the founding director of f2 vision management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2 vision. dr. jovan-embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f7 these securities are owned directly by f2 mg limited ("f2 mg"). globeways is the appointed manager of f2 mg. dr. jovan-embiricos is the founding director of globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2 mg. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f8 these securities are owned directly by f2-tpo investments, llc ("f2-tpo"). globeways holdings ii limited ("globeways ii") is the appointed manager of f2-tpo. dr. jovan-embiricos is the founding director of globeways ii and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2-tpo. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f9 these securities are owned directly by f2 bio td, llc ("f2 bio"). globeways ii is the appointed manager of f2 bio. dr. jovan-embiricos is the founding director of globeways ii and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2 bio. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f10 these securities are owned directly by f2 mc, llc ("f2 mc"). globeways ii is the appointed manager of f2 mc. dr. jovan-embiricos is the founding director of globeways ii and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2 mc. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f11 these securities are owned directly by f2 gc llc ("f2 gc"). globeways ii is the appointed manager of f2 gc. dr. jovan-embiricos is the founding director of globeways ii and has the sole power to vote upon the acquisition, holding and disposal of all shares held by f2 gc. each of the reporting persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f12 these securities are owned directly by dr. jovan-embiricos. each of the reporting persons except for dr. jovan-embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
WhaleWisdom Logo

Elevate your investments